Delta-Fly Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	6.4yrs

Recent management updates

Recent updates

CEO

Delta-Fly Pharma has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kinichiro Kominami	Independent Outside Director	5.9yrs	no data	no data
Kenzo Iizuka	Director	11.3yrs	no data	1.03% ¥ 62.8m
Sachio Kishii	Independent Outside Director	6.9yrs	no data	no data
Masaya Kimura	Auditor	9.9yrs	no data	0.18% ¥ 11.1m
Shohei Yamamoto	External Auditor	9.3yrs	no data	no data
Kenichi Kurotaki	Director	3.9yrs	no data	no data
Kiyoshi Eshima	President & Representative Director	no data	no data	no data
Akifumi Taniguchi	Independent Outside Director	2.9yrs	no data	no data
Masaaki Maeda	Full-Time Auditor	3.9yrs	no data	no data

6.4yrs

Average Tenure

56yo

Average Age

Experienced Board: 4598's board of directors are considered experienced (6.4 years average tenure).

Delta-Fly Pharma Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Recent updates

Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax

Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax (VTX) in the AML Patients Treated by VTX in the AML

Delta-Fly Pharma, Inc. to Report Fiscal Year 2024 Results on May 15, 2024

Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323

Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323

Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML

Delta-Fly Pharma, Inc. to Report Q3, 2024 Results on Feb 13, 2024

New major risk - Shareholder dilution

New major risk - Share price stability

Delta-Fly Pharma, Inc. to Report Q2, 2024 Results on Nov 13, 2023

Delta-Fly Pharma, Inc. to Report Q1, 2024 Results on Aug 14, 2023

Third quarter 2023 earnings released: JP¥75.09 loss per share (vs JP¥51.67 loss in 3Q 2022)

Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited

Delta-Fly Pharma, Inc. announced that it expects to receive ¥1.300842 billion in funding from Macquarie Group Limited

First half 2023 earnings released: JP¥115 loss per share (vs JP¥103 loss in 1H 2022)

Less than half of directors are independent

First quarter 2023 earnings released: JP¥56.83 loss per share (vs JP¥56.58 loss in 1Q 2022)

Delta-Fly Pharma, Inc. to Report Q3, 2023 Results on Feb 14, 2023

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Delta-Fly Pharma, Inc. to Report Fiscal Year 2022 Results on May 13, 2022

New 90-day low: JP¥1,067

New 90-day low: JP¥1,119

New 90-day low: JP¥1,521

CEO

Board Members

Average Tenure

Average Age